Back

Early discontinuation of P2Y12 antagonist and adverse clinical outcomes post percutaneous coronary intervention

19 April 2018 (08:30 - 18:00)
Organised by:
Congress Presentation Part of: Poster Session 1 - Coronary artery disease, acute coronary syndromes, acute cardiac care Coronary Artery Disease, Other EAPC Premium Access EuroPrevent 2018

About the speaker

Photo
Mr Daniel Harris

Swansea University, Swansea (United Kingdom of Great Britain & Northern Ireland)

12 More presentations in this session

Presentation thumbnail
Presentation thumbnail
Doctor B. Jonelid (Uppsala, SE)
Abstract Slides
Presentation thumbnail
Professor B. Jug (Ljubljana, SI)
Abstract
Presentation thumbnail
Professor O. Barbarash (Krasnodar, RU)
Abstract
Presentation thumbnail
Ms N. Buljubasic (Rotterdam, NL)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 1 - Coronary artery disease, acute coronary syndromes, acute cardiac care

The Event

Event poster

EuroPrevent 2018

19 April 2018 08:30 CET
You may be interested in
thumbnail
Congress Session
Dual antiplatelet therapy titration after percutaneous coronary intervention: when to escalate, de-escalate, withdraw, and more
28 August 2023
thumbnail
Congress Presentation
Outcome predictors in acute coronary syndrome in patients submitted to percutaneous coronary intervention
15 March 2025
thumbnail
Congress Presentation
Assessment of the antiplatelet effect of different p2y12 inhibitors using two methods at 30 and 120 minutes after oral loading in the cardiac catheterization laboratory
21 March 2026
thumbnail
Congress Presentation
Comparative discontinuation and non-bleeding side effects of Clopidogrel, Prasugrel and Ticagrelor in patients with acute coronary syndromes; a Network Meta-analysis of Randomized Controlled Trials
2 September 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources